Hepatitis: Clinical Trials

65 trials for Hepatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 unknown. 65 Phase 3, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 365Unknown 65
Phase 211Unknown 11

Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis

Trials (filtered) newest first · largest first

All 65 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
Glecaprevir/pibrentasvir, Placebo - PTSD
Phase 2 / Phase 3UnknownWhite River Junction Veterans Affairs Medical Center922023-12-182025-04-24
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL, HAVRIX 720 Junior 0.5 mL - Hepatitis A, Hep A
Phase 3UnknownBoryung Biopharma Co., Ltd.1062022-12-012022-11-14
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
N acetyl cysteine - Tuberculosis, Drug Induced Liver Injury
Phase 2 / Phase 3UnknownMahidol University822022-09-092023-02-22
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
Peginterferon Lambda-1a - Hepatitis Delta Virus
Phase 3UnknownEiger BioPharmaceuticals1502021-12-212023-08-25
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet, Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate - Chronic Hepatitis b
Phase 3UnknownXi'an Xintong Pharmaceutical Research Co.,Ltd.9002020-09-012020-09-10
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c
Phase 3UnknownAssiut University502019-09-012019-09-12
Micro-elimination of Hepatitis C Virus Infection in Uremics
Epclusa - Hepatitis C
Phase 3UnknownKaohsiung Medical University Chung-Ho Memorial Hospital1352019-05-132020-07-10
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic
Phase 2 / Phase 3UnknownNanjing Sanhome Pharmaceutical, Co., Ltd.4402019-03-292019-08-28
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity
Ribavirin, Tenofovir - Hepatitis B, Chronic
Phase 3UnknownOttawa Hospital Research Institute242019-01-102021-09-14
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
Seraprevir, Sofosbuvir - Hepatitis C Virus Infection
Phase 3UnknownGinkgopharma CO., LTD2062018-10-172019-06-28
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection
Phase 3UnknownJordan Feld402018-08-062019-07-12
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major
Phase 3UnknownAin Shams University242018-06-112023-03-06
Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation
4th dose of hexavalent vaccine 1 month after the 3rd dose - Haemopoietic Stem Cell Transplantation, Allograft
Phase 3UnknownUniversity Hospital, Grenoble2002018-05-012018-06-06
Fecal Microbial Transplantation in Severe Alcoholic Hepatitis
Fecal microbial transplantation - Alcoholic Hepatitis
Phase 3UnknownF.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica502018-04-012022-08-03
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG - Hepatitis B Infection
Phase 2 / Phase 3UnknownGreen Cross Corporation1862018-03-292020-01-30
Effect of Direct-acting Antiviral Drugs on Erectile Function
Sofosbuvir and Daklatasuvir - Hepatitis C
Phase 3UnknownSherief Abd-Elsalam1052018-01-012020-10-22
Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
Elbasvir/ Grazoprevir 50/100 mg fixed dose combination - Chronic Hepatitis C Genotype 1B, Metabolic Syndrome
Phase 3UnknownInstitute Of Cardiology & Internal Diseases, Kazakhstan602017-10-012017-08-07
Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
Administration of DAA-based treatment - Hepatocellular Carcinoma, Hepatitis C, Chronic
Phase 3UnknownAin Shams University802017-10-012018-06-11
Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients
Grazoprevir 100 mg/d 8 weeks, Elbasvir 50 mg/d 8 weeks, Grazoprevir 100 mg/d 12 weeks - Hepatitis C, HIV
Phase 3UnknownFundacion Clinic per a la Recerca Biomédica622017-04-282019-02-15
Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg), 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg) - Hepatitis C Virus Infection, Response to Therapy of
Phase 3UnknownEgyptian Liver Hospital802017-04-152018-05-24

Showing 20 of 65. Sign in to see all of them.

Narrower conditions

Hepatitis C (23)  ·  Hepatitis B, Chronic (15)  ·  Hepatitis C, Chronic (14)  ·  Hepatitis B (8)  ·  HIV Infections (5)  ·  Hepatitis, Alcoholic (4)  ·  Hepatitis A (3)  ·  Carcinoma, Hepatocellular (2)  ·  Chemical and Drug Induced Liver Injury (1)  ·  Chickenpox (1)  ·  Cholangiocarcinoma (1)  ·  Drug Misuse (1)  ·  Fatty Liver (1)  ·  Fibrosis (1)

Broader conditions

Digestive System Diseases (65)  ·  Liver Diseases (65)  ·  Infections (59)  ·  Virus Diseases (58)  ·  Hepatitis, Viral, Human (57)  ·  Blood-Borne Infections (54)  ·  Communicable Diseases (54)  ·  RNA Virus Infections (39)  ·  Flaviviridae Infections (33)  ·  Pathological Conditions, Signs and Symptoms (32)  ·  Pathologic Processes (31)  ·  Chronic Disease (29)  ·  Disease Attributes (29)  ·  Hepatitis, Chronic (28)

Interventions

Ribavirin (14)  ·  peginterferon alfa-2a (9)  ·  Sofosbuvir (8)  ·  Tenofovir (5)  ·  elbasvir (3)  ·  grazoprevir (3)  ·  Acetylcysteine (2)  ·  Metformin (2)  ·  Pentoxifylline (2)  ·  daclatasvir (2)  ·  entecavir (2)  ·  ledipasvir (2)  ·  peginterferon alfa-2b (2)  ·  ravidasvir (2)  ·  ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (1)

Sponsors

Ain Shams University (2)  ·  IRCCS San Raffaele (2)  ·  Kaohsiung Veterans General Hospital. (2)  ·  Mahidol University (2)  ·  Tel-Aviv Sourasky Medical Center (2)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Aalborg University Hospital (1)  ·  Assiut University (1)  ·  BioGeneric Pharma (1)  ·  Boryung Biopharma Co., Ltd. (1)  ·  Cairo University (1)  ·  Chiang Mai University (1)  ·  Chong Kun Dang Pharmaceutical (1)  ·  Clinical Research Organization, Dhaka, Bangladesh (1)  ·  Drugs for Neglected Diseases (1)

Countries

Egypt (9)  ·  China (8)  ·  South Korea (7)  ·  Thailand (5)  ·  France (4)  ·  Italy (4)  ·  Taiwan (4)  ·  Canada (3)  ·  Brazil (2)  ·  Germany (2)  ·  Israel (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Bangladesh (1)

Top investigators

Adriano Lazzarin, MD (2)  ·  Amanda Quevedo, Sub Coord (1)  ·  Bita Behnava, MD (1)  ·  Bradley V Watts, MD, MPH (1)  ·  Byung Seok Lee, M.D., Ph.D. (1)  ·  Curtis L Cooper, MD (1)  ·  Daiana V. Gomes, AssitSocial (1)  ·  Dong Joon Kim, M.D., Ph.D. (1)  ·  Gamal Esmat, M.D. (1)  ·  Gamal Esmat, MD (1)  ·  Gamal Shiha, MD (1)

Results publications

PMID 19811343, PMID 22170794, PMID 23109014, PMID 24265819, PMID 24431895, PMID 25469044, PMID 26860769, PMID 28404133, PMID 28935432, PMID 29682590, PMID 29998882, PMID 30133478, PMID 30448598, PMID 31711528, PMID 32245397, PMID 32355123, PMID 32389183, PMID 33303567, PMID 33493393, PMID 33865507, PMID 34186262, PMID 34307188, PMID 34807763, PMID 35080256, PMID 35149125, PMID 35867702, PMID 36586101, PMID 37856013, PMID 38046041, PMID 38473248, PMID 39662593, PMID 39663120, PMID 40665748, PMID 41144397, PMID 41335575, PMID 41366186

NIH funding

2015 (1)